Molecular basis of quantitative factor V deficiency associated with factor V R2 haplotype

Blood

Volumn 100, Issue 7, 2002, Pages 2515-2521

  Yamazaki, Tomio ^a,b   Nicolaes, Gerry A F ^a,b   Sørensen, Kristoffer W ^a,b   Dahlbäck, Björn ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; MUTANT PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; GLYCOSYLATION; GOLGI COMPLEX; HAPLOTYPE; HUMAN; IN VITRO STUDY; MISSENSE MUTATION; MOLECULAR MECHANICS; MUTATION RATE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; STEADY STATE;

EID: 0036786338     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.7.2515     Document Type: Article

References (35)

1. Rosing J, Tans G. Coagulation factor V: an old star shines again. Thromb Haemost. 1997;78:427-433.
2. Dahlback B. Procoagulant and anticoagulant properties of coagulation factor V: factor V Leiden (APC resistance) causes hypercoagulability by dual mechanisms. J Lab Clin Med. 1999;133:415-422.
3. Nicolaes GAF, Villoutreix BO, Dahlbäck B. Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity: modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation. Biochemistry. 1999;38:13584-13591.
4. Hoekema L, Nicolaes GAF, Hemker HC, Tans G, Rosing J. Human factor Va1 and factor Va2: properties in the procoagulant and anticoagulant pathways. Biochemistry. 1997;36:3331-3335.
5. Lunghi B, Iacoviello L, Gemmati D, et al. Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost. 1996;75:45-48.
6. Bernardi F, Faioni EM, Castoldi E, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood. 1997;90:1552-1557.
7. Alhenc-Gelas M, Nicaud V, Gandrille S, et al. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost. 1999;81:193-197.
8. Luddington R, Jackson A, Pannerselvam S, Brown K, Baglin T. The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C. Thromb Haemost. 2000;83:204-208.
9. De Visser MCH, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost. 2000;83:577-582.
10. Kostka H, Siegert G, Schwarz T. Frequency of polymorphisms in the B-domain of factor V gene in APC-resistant patients. Thromb Res. 2000;99:539-547.
11. Pecheniuk NM, Morris CP, Walsh TP, Marsh NA. The factor V HR2 haplotype: prevalence and association of the A4070G and A6755G polymorphisms. Blood Coagul Fibrinolysis 2001;12:201-206.
12. Castoldi E, Rosing J, Girelli D, et al. Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma. Thromb Haemost. 2000;83:362-365.
13. Zöller B, Svensson P, Dahlbäck B, Hillarp A. The factor V gene A4070G mutation is not associated with APC resistance or venous thrombosis among Swedish patients [abstract]. XVIII Congress of the International Society on Thrombosis and Haemostasis, Paris, France, July 2001. (http://www.cartesian-secure.com/isth2001/iAbstract/html/absP2218.html. Accessed June 27, 2002.)
14. Faioni EM, Franchi F, Bucciarelli P, et al. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor VR506Q. Blood. 1999;94:3062-3066.
15. Hoekema L, Castoldi E, Tans G, et al. Functional properties of factor V and factor Va encoded by the R2 gene. Thromb Haemost. 2001;85:75-81.
16. Jenny RJ, Pittman DD, Toole JJ, et al. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci U S A. 1987;84:4846-4850.
17. Pittman DD, Marquette KA, Kaufman RJ. Role of the B domain for factor VIII and factor V expression and function. Blood. 1994;84:4214-4225.
18. Shen NLL, Fan ST, Pyati J, Graff R, LaPolla RJ, Edgington TS. The serine protease cofactor factor V is synthesized by lymphocytes. J Immunol. 1993;150:2992-3001.
19. Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry. 1992;31:3777-3785.
20. Higuchi R. Recombinant PCR. In: Innis MA, Gelland DH, Sninsky JJ, White TJ, eds. PCR Protocols. San Diego, CA: Academic Press; 1990:177-183.
21. Ortel T, Moore KD, Ezban M, Kane WH. Effect of heterologous factor V heavy chain sequences on the secretion of recombinant human factor VIII. Thromb Haemost. 1996;75:36-44.
22. Espinosa-Parrilla Y, Yamazaki T, Sala N, Dahlback B, Garcia de Frutos P. Protein S secretion differences of missense mutants account for phenotypic heterogeneity. Blood. 2000;95:173-179.
23. Amano K, Sarkar R, Pemberton S, Kemball-Cook G, Kazazian H-H Jr, Kaufman R-J. The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2 domain of factor VIII. Blood. 1998;91:538-548.
24. Coligan JE. Post-translational modification: glycosylation. In: Coligan JE, Dunn BM, Ploegh HL, Speicher DW, Wingfield PT, eds. Current Protocols of Protein Science. New York, NY: John Wiley & Sons; 2000:12.0.1-12.7.15.
25. Castaman G, Lunghi B, Missiaglia E, Bernardi F, Rodeghiero F. Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506GIn (factor V Leiden) and His1299Arg substitutions in factor V. Br J Haematol. 1997;99:257-261.
26. Yamazaki T, Katsumi A, Kagami K, et al. Molecular basis of a hereditary type I protein S deficiency caused by a substitution of Cys for Arg474. Blood. 1996;87:4643-4650.
27. Katsumi A, Senda T, Yamashita Y, et al. Protein C Nagoya, an elongated mutant of protein C, is retained within the endoplasmic reticulum and is associated with GRP78 and GRP94. Blood. 1996;87:4164-4175.
28. Tokunaga F, Wakabayashi S, Koide T. Warfarin causes the degradation of protein C precursor in the endoplasmic reticulum. Biochemistry. 1995;34:1163-1170.
29. Katsum A, Matsushita T, Yamazaki T, Sugiura I, Kojima T, Saito H. Severe factor VII deficiency caused by a novel mutation His348 to Gin in the catalytic domain. Thromb Haemost. 2000;83:239-243.
30. Kondo S, Tokunaga F, Kawano S, Oono Y, Kumagai S, Koide T. Factor XII Tenri, a novel crossreacting material negative factor XII deficiency, occurs through a proteasome-mediated degradation. Blood. 1999;93:4300-4308.
31. Shirotani H, Tokunaga F, Koide T. Cellular and functional characterization of three recombinant antithrombin mutants that caused pleiotropic effect-type deficiency. J Biochem. 1999;125:253-262.
32. Pittman DD, Tomkinson KN, Kaufman RJ. Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells. J Biol Chem. 1994;269:17329-17337.
33. Ellgaard L, Molinari M, Helenius A. Setting the standards: quality control in the secretory pathway. Science. 1999;286:1882-1888.
34. Chevet E, Cameron P, Pelletier M, Thomas DY, Bergeron JJM. The endoplasmic reticulum: integration of protein foldong, quality control, signaling and degradation. Curr Opin Struct Biol. 2001;11:120-124.
35. Kaufman RJ. Post-translational modifications required for coagulation factor secretion and function. Thromb Haemost. 1998;79:1068-1079.